HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model.

Abstract
Concomitant chemotherapy and radiotherapy (CCRT) has recently been shown to improve treatment outcome in a range of solid tumors. Pegylated liposomes have the potential to target drugs directly to tumors and may increase the efficacy and reduce the toxicity of CCRT by selectively delivering radiosensitizing agents to tumor, as opposed to normal, tissues. In these studies, we have assessed CCRT using pegylated liposome encapsulated doxorubicin (PLED) and pegylated liposome encapsulated cisplatin (PLEC) against KB head and neck cancer xenograft tumors in nude mice. The addition of low-dose (2 mg/kg) PLED (P < 0.001) and PLEC (P < 0.001) significantly increased the effect of 4.5 Gy, but not 9 Gy, single-fraction radiotherapy (SFRT). Both PLED and PLEC were significantly more effective than their unencapsulated counterparts in increasing the effect of SFRT. In addition, PLED (P < 0.001) and PLEC (P < 0.05) significantly increased the effect of fractionated radiotherapy (9 Gy in 3 fractions) in two different dosing schedules (2 mg/kg single dose or three sequential doses of 0.67 mg/kg). Unencapsulated diethylenetriaminepentaacetic acid and pegylated liposomal diethylenetriaminepentaacetic acid were used as controls to test the effect of the liposome vehicle and showed no interaction with 4.5 Gy or 9 Gy SFRT (P > 0.1). CCRT was well-tolerated, with no evidence of increased local or systemic toxicity, as compared with radiotherapy alone. This study is the first to demonstrate the value of pegylated liposomes as vehicles for the delivery of radiosensitizing drugs in CCRT strategies.
AuthorsK J Harrington, G Rowlinson-Busza, K N Syrigos, R G Vile, P S Uster, A M Peters, J S Stewart
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 6 Issue 12 Pg. 4939-49 (Dec 2000) ISSN: 1078-0432 [Print] United States
PMID11156255 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Liposomes
  • Radiation-Sensitizing Agents
  • Polyethylene Glycols
  • Doxorubicin
  • Cisplatin
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Cisplatin (administration & dosage, therapeutic use)
  • Combined Modality Therapy
  • Dose-Response Relationship, Drug
  • Dose-Response Relationship, Radiation
  • Doxorubicin (administration & dosage, therapeutic use)
  • Head and Neck Neoplasms (drug therapy, radiotherapy)
  • Humans
  • Liposomes (chemistry)
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Polyethylene Glycols (chemistry)
  • Radiation Tolerance (drug effects)
  • Radiation-Sensitizing Agents (administration & dosage, therapeutic use)
  • Time Factors
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: